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Obesity is associated with an inflammatory status and linked with a number of
pathophysiological complications among them cardiovascular disease, type 2 diabetes
mellitus, or the metabolic syndrome. Resveratrol was proposed to improve obesity-
related inflammatory problems, but the effect of resveratrol on cytokine expression in
obesity is not completely understood. In this study, we used an in vitro model of human
adipose tissue inflammation to examine the effects of resveratrol on the production
of the inflammatory cytokines interleukin 6 (IL-6), IL-8, and monocyte chemoattractant
protein 1 (MCP-1). We found that resveratrol reduced IL-6, IL-8, and MCP-1 levels in a
concentration-dependent manner in adipocytes under inflammatory conditions. Further
experiments showed that the action of resveratrol was mainly due to its NFκB inhibitory
potential. Thus, our data support the concept that resveratrol can alleviate obesity-
induced up-regulation of inflammatory cytokines providing a new insight toward novel
treatment options in obesity.
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Introduction
During the last 20 years obesity became a major public health problem in advanced and developing
countries (De Ferranti and Osganian, 2007). Obesity is characterized by an excessive accumula-
tion of white adipose tissue. While the total body composition of lean adult men consists of about
20% adipose tissue, the latter can increase to more than 40% in obese men. In addition to their
fat storing and releasing capacity, white adipocytes represent endocrine cells that secrete a diverse
range of adipokines and cytokines. Indeed, adipokines are involved in the regulation of various
functions, including appetite, insulin sensitivity, angiogenesis, blood pressure, and the immune
response (Maury and Brichard, 2010). As such, it is not surprising that cardiovascular disease, type
2 diabetes mellitus, the metabolic syndrome, and various cancers are ultimately linked to dyslipi-
demia, hyperglycemia, hypertension, and a pro-inﬂammatory state (De Ferranti and Osganian,
2007).
This endocrine function of the adipose tissue implicates that adipocytes communicate with
other tissues and cells in a bidirectional manner. This appears to be central during development
of an inﬂammatory state in the adipocyte tissue which upon excessive expansion is inﬁltrated
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by macrophages (Bouloumie et al., 2005). The inﬁltrated
macrophages secrete inﬂammatory cytokines thereby leading
to a local and systemic inﬂammation. In turn, this inﬂamma-
tion induces expression and secretion of cytokines like inter-
leukin 6 (IL-6), IL-8, and monocyte chemoattractant protein
1 (MCP-1) from the adipocytes. Importantly, the levels of
circulating IL-6, IL-8, and MCP-1 were shown to correlate
with a higher body mass index (BMI; Herder et al., 2005;
Warnberg et al., 2006; Derosa et al., 2013). Further, over-
production of IL-6 and MCP-1 by inﬂamed adipocytes could
be directly linked with development of type 2 diabetes in
obese patients where the paracrine action of MCP-1 decreases
PPARγ expression thus leading to enhanced insulin resistance
of adipocytes (Serrano-Marco et al., 2012). In addition, ele-
vated plasma levels of IL-8 are associated with atherosclerosis
and an increased risk of arterial plaque formation (Kobashi
et al., 2005; Yang et al., 2006). When obese patients undergo
calorie restriction, the levels of IL-6, IL-8, and MCP-1 appear
to decrease implying that calorie restriction has a beneﬁ-
cial eﬀect on the inﬂammatory state (Larson-Meyer et al.,
2008).
Resveratrol, a natural polyphenolic compound, produced by
plants in response to environmental stress and found in red grape
skin, peanuts, a variety of berries and medical plants (Signorelli
and Ghidoni, 2005) gained special interest as a calorie restric-
tion mimetic based on data from rodents. When mice and/or
rats were fed a high-fat diet, resveratrol treatment improved glu-
cose homeostasis, mitochondrial function, lipid parameters, body
weight, and survival (Baur et al., 2006; Lagouge et al., 2006;
Barger et al., 2008; Pearson et al., 2008; Rivera et al., 2009; Rocha
et al., 2009). While the resveratrol eﬀects are intensively studied
in animal models only few clinical trials were conducted so far
to study the eﬀects of resveratrol supplementation in the con-
text of human obesity and coronary artery disease (Timmers
et al., 2011; Tome-Carneiro et al., 2013b), yet there exists some
controversy (Poulsen et al., 2013) and the eﬀect of resveratrol
on the expression of inﬂammatory cytokines, in particular IL-6,
IL-8, and MCP-1 in obesity remains to be further investigated.
Therefore it was the aim of this study to investigate the eﬀects
of resveratrol on the production of IL-6, IL-8, and MCP-1 in
human adipocytes and in an in vitromodel of human adipose tis-
sue inﬂammation. We found that resveratrol reduces IL-6, IL-8,
and MCP-1 levels in adipocytes under inﬂammatory conditions.
Thus, our data support the concept that resveratrol can allevi-
ate obesity-induced up-regulation of inﬂammatory cytokines in
adipocytes.
Materials and Methods
Materials
All chemicals and reagents were obtained from commer-
cial suppliers. Cell culture media and supplements were
purchased from Invitrogen Life Technologies (Darmstadt,
Germany). Resveratrol and LY294002 were obtained from Sigma
(Deisenhofen, Germany), SC-514 was from Merck Millipore
(Darmstadt, Germany). All the chemicals were diluted in
DMSO which alone was used as a vehicle control. The fol-
lowing concentrations of the chemicals were used: for resver-
atrol, 10, 30, and 100 μM; for LY294002, 20 μM; for SC-514,
100 μM.
Cell Culture
Human primary preadipocytes were prepared by collagenase
digestion from subcutaneous adipose tissue of four healthy
women using a previously described protocol (Hauner et al.,
2001). Procedures were approved by the ethical committee of
the University of Ulm and patients gave written informed con-
sent. Simpson–Golabi–Behmel syndrome (SGBS) preadipocytes
were cultured as described previously (Wabitsch et al., 2001;
Fischer-Posovszky et al., 2008). These cells were used because
they provide so far the only human preadipocyte model with
high capacity for adipose diﬀerentiation. Adipogenic diﬀerenti-
ation of SGBS and human primary preadipocytes was induced in
serum-free DMEM/F12 medium supplemented with 10 μg/mL
iron-poor transferrin, 10 nM insulin, 200 pM thyroid hormone,
and 0.1 μM cortisol. For the ﬁrst 4 days 2 μM rosiglitazone,
250 μM isobutylmethylxanthine, and 25 nM dexamethasone was
added. Morphologically diﬀerentiated adipocytes were used for
experiments 8 days after initiation of adipogenic diﬀerentiation
(Figure 1A). The number of diﬀerentiated cells was estimated
in the monolayers by direct counting using a net micrometer.
SGBS cultures were used for experiments when diﬀerentiation
rate was ≥85%.
THP-1 cells (ATCC, Wesel, Germany) were cultured as
described earlier (Kotnik et al., 2013). Diﬀerentiation into
macrophages was induced by 125 ng/mL phorbol-12 myristate
13-acetate (PMA) for 48 h. Macrophage-conditioned medium
(MacCM) was collected after additional 48 h of incubation in
serum-free basal medium containing 0.5% BSA and cleared by
centrifugation. MacCM from ﬁve independently performed pro-
ductions was pooled and then used for experiments. Serum-free
basal medium containing 0.5% BSA was also used as a vehicle
control at the corresponding concentrations.
Coculture experiments of SGBS adipocytes with THP-1
macrophages were performed as described before (Kotnik
et al., 2013). In vitro diﬀerentiated THP-1 macrophages were
trypsinized and added to cultures of SGBS adipocytes (at day 9 of
the adipogenic diﬀerentiation); diﬀerent ratios between the SGBS
and THP-1 cells were set up (SGBS:THP-1; 100:3, 100:10, 100:30).
Treatment with resveratrol occurred for 48 h if not otherwise
stated in the legends to the ﬁgures.
Expression Analysis of mRNA by
Quantitative Real-Time PCR (qRT-PCR)
Total RNA was prepared using the peqGOLD HP Total
RNA kit (Peqlab, Erlangen, Germany) following the man-
ufacturer’s instructions. One microgram of total RNA
was used for cDNA synthesis with using SuperScript II
Reverse Transcriptase (Invitrogen, Darmstadt, Germany).
Quantitative real-time PCR (qRT-PCR) was performed with a
LightCyclerTM 2.0 (Roche Diagnostics, Mannheim, Germany)
using a LightCycler FastStart DNA Master PLUS SYBR
Green I kit (Roche Diagnostics, Mannheim, Germany).
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FIGURE 1 | Induction of interleukin 6 (IL-6), IL-8, and monocyte
chemoattractant protein 1 (MCP-1) expression in an in vitro model of
human inflamed adipose tissue. (A) Scheme of the Simpson–Golabi–
Behmel syndrome (SGBS) cell differentiation protocol. For details see
“Materials and Methods.” (B) SGBS adipocytes were incubated for 48 h with
increasing ratios of THP-1 macrophages. The mRNA levels were analyzed by
qPCR and results were normalized to hypoxanthine
phosphoribosyltransferase (HPRT). Data from three independent experiments
are presented as mean ± SD. ∗p < 0.05 SGBS alone vs. SGBS:THP-1 or
THP-1. (C) The accumulation of IL-6, IL-8, and MCP-1 in the media was
measured by ELISA after coincubation with THP-1 cells for 24 h. (D) SGBS
adipocytes were incubated with increasing doses of macrophage-conditioned
media (MacCM) or vehicle for 48 h. The mRNA levels were analyzed by
qPCR and results were normalized to HPRT. ∗Significant difference control
vs. MacCM. (E) SGBS adipocytes were incubated for 48 h with increasing
concentrations of MacCM or vehicle control. Representative images of SGBS
cells after treatment are shown. (E) Scheme of the SGBS cell differentiation
protocol. For details see “Materials and Methods.”
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The qRT-PCR results were normalized using hypoxan-
thine phosphoribosyltransferase (HPRT) as a housekeeping
gene. The following primer sets were used: HPTR-forw (5′-
GAGATGGGAGGCCATCACATTGTAGCCCTC-3′), HPRT-rev
(5′-CTCCACCAATTACTTTTATGTCCCCTGTTGACTGGTC-
3′), IL-6-forw (5′-TATACCCCCAGGAGAAGATTCC-3′), IL-
6-rev (5′-TTTTCTGCCAGTGCCTCTTT-3′), IL-8-forw (5′-
TGCCAAGGAGTGCTAAAGAACTTAGATGTCAG-3′), IL-8-
rev (5′-AGCTTTACAATAATTTCTGTGTTGGCGCAGTG-3′),
MCP-1-forw (5′-TCCCAAAGAAGCTGTGATCTTCAAGACC-
3′),MCP-1-rev (5′-AGTGAGTGTTCAAGTCTTCGGAGTTTGG-
3′). The experiments for each data point were carried out in
triplicate. The relative quantiﬁcation of gene expression was
determined using the Ct method.
ELISA
Protein secretion of IL-6, IL-8, and MCP-1 was measured in
the supernatant. For determining the IL-6 and IL-8 concentra-
tion in the supernatant the commercially available IL-6, and IL-8
ELISA kits (BioSource, Nivelles, Belgium) were used accord-
ing to the manufacturer’s protocols. The MCP-1 protein levels
were determined using the Human CCL2 (MCP-1) ELISAReady-
SET-Go! R© kit (eBioscience, Frankfurt, Germany) following the
manufacturer’s instructions.
Statistics
Data are represented as mean ± SEM of three diﬀerent exper-
iments unless it is otherwise stated. Statistical signiﬁcance was
calculated by using one way analysis of variants (ANOVA) and
Dunnet or Tukey correction test, where p < 0.05 was considered
as statistically signiﬁcant.
Results
The Cytokines IL-6, IL-8, and MCP-1 are
Upregulated in an In Vitro Model of Human
Inflamed Adipose Tissue
Obesity is associated with low grade chronic inﬂammation
(Gregor and Hotamisligil, 2011) and in order to mimic this
in human adipose tissue we ﬁrst investigated whether direct
cell interactions between macrophages and adipocytes have
an impact on IL-6, IL-8, and MCP-1 expression. To do this,
we used a coculture model in which we cocultured SGBS
adipocytes directly with THP-1 macrophages in the following
ratios (SGBS:THP-1; 100:3, 100:10, 100:30). Coculture of SGBS
adipocytes with THP-1 cells increased IL-6, IL-8, and MCP-
1 expression in a THP-1 cell-dependent manner. When the
SGBS:THP-1 ratio was 100:30 the IL-6 mRNA was induced by
about 45-fold, IL-8 mRNA was induced by about 1200-fold,
and MCP-1 mRNA was induced by about 20-fold (Figure 1B).
The mRNA expression was followed by the protein expres-
sion and increased IL-6, IL-8, and MCP-1 levels could be
measured in the media. By contrast, THP-1 cells alone did
not secrete signiﬁcant amounts of IL-6, IL-8, and MCP-1 sug-
gesting that adipocytes would be the source of the cytokines
(Figure 1C).
Next we examined whether macrophage released media-
tors are able to cause an enhanced IL-6, IL-8, and MCP-1
expression in the adipocytes. Therefore, we incubated SGBS
adipocytes with medium supplemented with increasing con-
centrations of MacCM for 48 h (Keuper et al., 2011). Next,
we measured expression of IL-6, IL-8, and MCP-1 in SGBS
adipocytes upon treatment with MacCM. MacCM induced a
concentration-dependent up-regulation of IL-6, IL-8, and MCP-
1 expression. While the presence of 5% MacCM already sig-
niﬁcantly increased IL-6, and MCP-1 mRNA levels by about
20-fold and 10-fold, respectively, 10% MacCM induced IL-6
mRNA by about 50-fold, IL-8 mRNA by about 90-fold and
MCP-1 mRNA by about 20-fold compared to vehicle control
(Figure 1D). Treatment of SGBS adipocytes with MacCM also
induced morphological changes toward a more dediﬀerentiated
ﬁbroblast-like phenotype in a concentration-dependent man-
ner. Especially higher concentrations of MacCM (20%) caused
lipid loss from the adipocytes (Figure 1E) which was fur-
ther conﬁrmed by a reduced number of lipid ﬁlled adipocytes
by morphological counting and an accumulation of free glyc-
erol in the media supernatants suggesting a loss of lipids by
lipolysis (data not shown) as shown earlier (Kotnik et al.,
2013); therefore we conducted further experiments with 10%
MacCM.
Together, these data show that macrophage releasedmediators
induce IL-6, IL-8, and MCP-1 expression in adipocytes.
Resveratrol Abolishes the Increased
Expression of IL-6, IL-8, and MCP-1 in an
In vitro Model of Human Inflamed Adipose
Tissue
To determine the eﬀect of resveratrol on the increased expres-
sion of IL-6, IL-8, and MCP-1, we ﬁrst cocultured SGBS
adipocytes directly with THP-1 macrophages (SGBS:THP-1;
100:30) in the presence or absence of resveratrol (100 μM).
While coculture of SGBS adipocytes with THP-1 cells increased
IL-6, IL-8, and MCP-1 expression resveratrol abolished the
induced cytokine expression on the mRNA and protein
level in the coculture model of inﬂamed adipose tissue
(Figures 2A,B).
We next examined whether the resveratrol eﬀect is also
present in the MacCM treated SGBS adipocytes. Therefore,
SGBS cells were cultured with 10% MacCM either in the
absence or presence of diﬀerent concentrations of resvera-
trol (10, 30, 100 μM) for 48 h. MacCM treatment induced
IL-6 mRNA by about 50-fold, IL-8 mRNA by about 140-
fold, and MCP-1 mRNA by about 25-fold. Treatment of
SGBS adipocytes with MacCM and increasing doses of resver-
atrol resulted in a concentration-dependent reduction of
cytokine expression when compared to MacCM treatment
alone: IL-6 mRNA expression was reduced to about 10-
fold, IL-8 mRNA to about eightfold and MCP-1 mRNA
to about ﬁvefold when treated with 100 μM resveratrol
(Figure 2C).
Thus, these data indicate that resveratrol is able to reduce the
inﬂammation associated expression of IL-6, IL-8, and MCP-1 in
adipocytes.
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FIGURE 2 | Resveratrol (Res) abolished the macrophage and
MacCM-dependent IL-6, IL-8, and MCP-1 induction in SGBS adipocytes
and primary human ex vivo differentiated adipocytes. (A) SGBS
adipocytes were incubated for 48 h with THP-1 macrophages (100:30) and
treated with 100 μM Res. The mRNA levels were analyzed by qPCR and results
were normalized to HPRT. ∗Significant difference control vs. coculture
(SGBS:THP-1; 100:30). ∗∗Significant difference coculture vs. coculture+Res
(B) The accumulation of IL-6, IL-8, and MCP-1 in the media was measured by
ELISA after coincubation with THP-1 cells and/or treatment with Res for 48 h.
(C) SGBS adipocytes were incubated for 48 h with 10% MacCM or a
combination of different doses of Res and 10% MacCM. The mRNA levels were
analyzed by qPCR and results were normalized to HPRT. ∗Significant difference
untreated vs. Res or MacCM, ∗∗Significant difference MacCM treated vs.
MacCM +Res. (D) Primary human differentiated adipocytes were incubated for
48 h with 10% MacCM or 100 μM Res and 10% MacCM. The mRNA levels
were analyzed by qPCR and results were normalized to HPRT. ∗Significant
difference untreated vs. Res or MacCM, ∗∗Significant difference MacCM treated
vs. MacCM +Res.
Frontiers in Pharmacology | www.frontiersin.org 5 April 2015 | Volume 6 | Article 79
Zagotta et al. Obesity and resveratrol
Resveratrol Abolishes the Increased
Expression of IL-6, IL-8, and MCP-1 in
Primary Adipocytes from Obese Patients
In order to demonstrate that the resveratrol eﬀect is not limited
to the SGBS cell model system of inﬂamed adipose tissue, we
used human primary ex vivo diﬀerentiated adipocytes from four
patients and incubated them with 10%MacCM in the presence or
absence of resveratrol (100μM) for 48 h. The IL-6mRNA expres-
sion was induced by about 35-fold, the IL-8 mRNA was induced
by about 320-fold, and MCP-1 mRNA expression was induced
by about sevenfold. Treatment with resveratrol diminished the
MacCM-dependent expression of IL-6, IL-8, and MCP-1 to six-
fold, eightfold, and twofold, respectively (Figure 2D).
PI3K Inhibition Only Affects MCP-1 but Not
IL-6 and IL-8 Expression
Resveratrol has been shown to aﬀect several pathways from
which the PI3K/Akt pathway (Kang et al., 2010; Mader et al.,
2010; Miranda et al., 2010; Wang et al., 2011) appears to be
of importance in an inﬂammatory setting. To examine whether
PI3K is involved in the resveratrol-dependent inhibition of
IL-6, IL-8, and MCP-1 gene expression, we incubated SGBS
adipocytes with the PI3K inhibitor LY294002 (20 μM) along
with resveratrol (100 μM), MacCM (10%) or their combinations
and determined IL-6, IL-8, and MCP-1 mRNA levels 48 h after
treatment. While resveratrol decreased IL-6, IL-8, and MCP-1
mRNA levels by more than 80% compared to MacCM treat-
ment alone, treatment with LY294002 decreased only MCP-1
mRNA and protein levels by 50% and by about 70%, respec-
tively, but did not decrease IL-6 and IL-8 mRNA expression; on
protein level it decreased IL-6 expression by 13% and IL-8 by
28%. Thus, these data indicate that the action of resveratrol on
IL-6 and IL-8 expression is rather not PI3K pathway dependent
(Figure 3).
Resveratrol Abolishes the Increased
Expression of IL-6, IL-8, and MCP-1 by
Acting Like an NFκB Inhibitor
The reduction of IL-6, IL-8, and MCP-1 expression by resvera-
trol under inﬂammatory conditions may be partially explained
by the ability of resveratrol to suppress the activity of NFκB,
a transcription factor critically involved in inﬂammation. We
have shown previously that resveratrol is able to inhibit nuclear
translocation of NFκB in SGBS adipocytes (Zagotta et al., 2013).
Therefore, we further explored the role of NFκB on IL-6, IL-8,
andMCP-1 production in SGBS adipocytes treated with MacCM,
FIGURE 3 | The effects of Res on MCP-1 but not IL-6, and IL-8 gene
expression in SGBS adipocytes are mediated via PI3K. (A) Where
indicated SGBS adipocytes were treated with a combination of 10% MacCM
and 20 μM LY294002, or 100 μM Res for 48 h. The mRNA levels were
analyzed by qPCR and results were normalized to HPRT. ∗Significant difference
control vs. treated ∗∗significant difference MacCM vs. MacCM +Res or
MacCM+LY204002. (B) The accumulation of IL-6, IL-8, and MCP-1 in the
media was measured by ELISA after treatment with 10% MacCM and/or 20 μM
LY294002, 100 μM Res for 48 h. ∗Significant difference control vs. treated
∗∗significant difference MacCM vs. MacCM +Res or MacCM + LY204002.
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FIGURE 4 | Resveratrol acts like an NFkB inhibitor suppressing the
MacCM-dependent IL-6, IL-8, and MCP-1 gene expression. (A) SGBS
adipocytes were treated with 10% MacCM, a combination of both Res (100 μM)
and 10% MacCM, or a combination of SC-514 (100 μM) and MacCM for 48 h.
The mRNA levels were analyzed by qPCR and results were normalized to HPRT.
∗Significant difference control vs. treated ∗∗significant difference MacCM vs.
MacCM +Res or MacCM+SC-514. (B) The accumulation of IL-6, IL-8, and
MCP-1 in the media was measured by ELISA after treatment with 10% MacCM
and/or 100 μM SC-514, 100 μM Res for 48 h. ∗Significant difference control vs.
treated ∗∗significant difference MacCM vs. MacCM +Res or MacCM+SC-514.
resveratrol, and the NFκB inhibitor SC-514 alone or in combi-
nation. The expression of IL-6, IL-8, and MCP-1 was assayed by
qPCR and ELISA. The treatment with the NFκB inhibitor SC-514
reduced MacCM-dependent IL-6, IL-8, and MCP-1 induction
(Figure 4A), Further, resveratrol exhibited a strong reduction
on the MacCM-dependent IL-6, IL-8, and MCP-1 induction on
the mRNA and protein level. Together, these data suggest that
resveratrol inhibits the MacCM-dependent IL-6, IL-8, and MCP-
1 induction at least to a large extend via its NFκB inhibitory
potential (Figure 4).
Discussion
In this study we investigated the human IL-6, IL-8, and MCP-1
expression in amodel of inﬂamed human adipose tissue. Our data
demonstrated several new ﬁndings on the expression of IL-6, IL-
8, and MCP-1 under obesity-mimicking conditions. First, it was
found that macrophage-released mediators and not direct cell
contacts are responsible for the enhanced expression of IL-6, IL-
8, and MCP-1 in SGBS adipocytes. Second, resveratrol strongly
inhibited the obesity-associated and inﬂammation-dependent
induction of IL-6, IL-8, and MCP-1 in SGBS adipocytes. Third,
resveratrol acted to a large extend like an NFκB inhibitor but less
like a PI3K inhibitor on the inﬂammatory-dependent IL-6, IL-8,
and MCP-1 expression.
Obesity represents a risk factor for the development of dis-
eases like type 2 diabetes mellitus, hypertension, atherosclerosis,
and myocardial infarction. Intriguingly, obesity is also associ-
ated with a state of chronic low-grade inﬂammation charac-
terized by elevated plasma concentrations of pro-inﬂammatory
cytokines (IL-6, IL-1, and TNF-α), chemokines (MCP-1) and
adipokines (haptoglobin, PAI-1, leptin, visfatin, resistin, and
VEGF; Hotamisligil, 2006). Plasma IL-6, IL-8, and MCP-1 levels
are considerably enhanced in obese humans and in patients with
insulin resistance, type 2 diabetes, and cardiovascular diseases
(Skurk et al., 2002; Lyon and Hsueh, 2003). It is estimated that
about 35% of obesity-related IL-6 in serum is secreted from adi-
pose tissue (Mohamed-Ali et al., 1997). Indeed, the present data
in accordance with previous reports (Path et al., 2001; Vicennati
et al., 2002; Ajuwon et al., 2004; Deo et al., 2004; Ajuwon and
Spurlock, 2005; Fain and Madan, 2005) indicate that adipocytes
can produce substantial amounts of IL-6, IL-8, and MCP-1.
Although all these data indicate that the adipocytes appear
to be the major source of elevated IL-6, IL-8, and MCP-1
levels observed in obesity (Shimomura et al., 1996; Morange
et al., 1999), it is still a matter of debate whether this is a
result of stimulation of adipocytes via direct cell contacts with
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macrophages or an eﬀect caused by hormones and cytokines
released from the macrophages (Loskutoﬀ and Samad, 1998).
The current study shows that direct cell contacts between THP-1
macrophages and adipocytes are of less importance since incu-
bation of adipocytes with only the THP-1 conditioned medium
was enough to cause enhanced IL-6, IL-8, andMCP-1 expression.
In turn, the THP-1 released cytokines present in the MacCM, in
particular TNFα, may play a role in the lipolysis observed in the
current study.
New aspects in obesity treatment consider to reduce the
inﬂammatory burden and to reduce cytokine expression in
adipocyte by use of natural compounds. Resveratrol is such
a compound which is at least capable to change the obesity-
associated secretion proﬁle of adipocytes (Ahn et al., 2007;
Olholm et al., 2010; Yen et al., 2011; Rosenow et al., 2012). In
particular resveratrol inhibited TNF-α-dependent upregulation
of the acute phase protein PAI-1 in 3T3-L1 adipocytes (Ahn et al.,
2007; Olholm et al., 2010; Yen et al., 2011; Rosenow et al., 2012),
and PAI-1 production in human SGBS adipocytes (Rosenow
et al., 2012; Zagotta et al., 2013). These data are very much
in line with the results from the present study where we have
shown that resveratrol exerted a very pronounced eﬀect on IL-
6, IL-8, and MCP-1 expression in a model of inﬂamed human
adipose tissue (Figures 2 and 3). Although all these data indi-
cate that resveratrol can alleviate obesity-induced upregulation
of IL-6, IL-8, and MCP-1 in adipose tissue, it has not been fully
elucidated by which molecular mechanisms resveratrol exerts its
eﬀect on IL-6, IL-8, and MCP-1 under inﬂammatory conditions.
Resveratrol is known to exert pleiotropic eﬀects on cells via Sirt1
(Picard et al., 2004; Fischer-Posovszky et al., 2010), AMPK (Wang
et al., 2011; Lasa et al., 2012), and PI3K/Akt (Kang et al., 2010;
Mader et al., 2010; Miranda et al., 2010) and nuclear factor (NF)
κB. However, our recent investigation with SGBS adipocytes has
shown that Sirt1, and AMPK were not the major mediators of
the resveratrol eﬀects on PAI-1 synthesis under inﬂammatory
conditions (Zagotta et al., 2013). Indeed a number of studies
indicated that the PI3K/Akt pathway represents an important
signaling cascade in the initiation of the inﬂammatory response.
Although we showed in an earlier study that resveratrol inhibits
PI3K-driven Akt phosphorylation in SGBS cells (Mader et al.,
2010) like the PI3K inhibitor, LY294002, the present study shows
that LY294002, in contrast to resveratrol, could not abrogate the
MacCM-dependent up-regulation of IL-6, and IL-8. LY294002
had only an eﬀect on MCP-1 (Figure 3B) implicating that inhi-
bition of the PI3K/Akt pathway by resveratrol is not involved
in the attenuating eﬀect on MacCM-dependent IL-6, IL-8, and
MCP-1 expression. The reason for this diﬀerent pattern is not
entirely clear. One option could be that the eﬀect of PI3K inhi-
bition on MCP1 was more direct via a PI3K or Akt regulated
transcription factor whereas it was rather indirect or involving
PI3K regulated feed back circuits with IL6 and IL8. For example
if there are some suppressors of IL6 and IL8 expression which
are regulated by PI3K, their inhibition by PI3K inhibitors would
have a positive eﬀect on IL6 and IL8 expression. Overall, the net
result would be that PI3K inhibition has no eﬀect on IL6 and IL8
expression.
An increase in plasma IL-6, IL-8, and MCP-1 levels observed
in obesity can also be the result of a cytokine-dependent induc-
tion of NFκB, a transcription factor with a central role in the
induction of a chronic inﬂammatory state associated with obe-
sity, development of type 2 diabetes, cardiovascular risk, and
insulin resistance (Gonzales andOrlando, 2008). Previous reports
including our own indicated that resveratrol can act as an
inhibitor of NFκB (Kundu and Surh, 2004; Tome-Carneiro et al.,
2013a). The data of the present study showing that resveratrol
behaves like an established NFκB inhibitor and reduces more or
less completely the MacCM-dependent expression of IL-6, IL-8,
and MCP-1 are in line with those ﬁndings. This places NFκB in a
central position to be the mediator of obesity-associated inﬂam-
matory eﬀects and links a number of in vivo and in vitro studies
showing an inhibitory role of the resveratrol targets Sirt1, and
AMPK on NFκB (Pﬂuger et al., 2008; Yoshizaki et al., 2009; Zhu
et al., 2011; Lin et al., 2012; references in Salminen et al., 2011).
Although several previous ﬁndings have demonstrated that the
PI3K/Akt pathway has a crucial role in the activation of the NFκB
pathway (Ozes et al., 1999; Madrid et al., 2001) our current data
suggest that the PI3K/Akt pathway is less dominantly involved in
the MacCM-dependent expression of the IL-6, and IL-8 genes.
Together, our current ﬁndings add at least one novel aspect to
the pleiotropy of the resveratrol eﬀects by showing that it can act
as an anti-inﬂammatory molecule blocking the NFκB-dependent
expression of the inﬂammatory cytokines IL-6, IL-8, and MCP-
1 in an in vitro model of human inﬂamed adipose tissue. These
ﬁndings may be useful to further establish IL-6, IL-8, and MCP-1
as markers for obesity-associated inﬂammatory conditions.
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